Celltrion abandoned clinical trials of CT-P59
By Lee, Jeong-Hwan | translator Choi HeeYoung
21.02.25 10:44:48
가나다라
0
After the government project was selected in December of last year, a waiver was submitted to the KDDF
"It was difficult to recruit patients for clinical trials"
Urgent need for national support for severe COVID-19 treatment
It was found that Celltrion gave up the clinical trial of CT-P59, a prophylactic antibody treatment to respond to COVID-19.
Celltrion decided to suspend the project selection agreement in less than a month after it was selected for the government support project in December of last year.
Celltrion cited the difficulty of developing vaccines from global pharmaceutical companies and recruiting patients for clinical trials as a reason for giving up clinical trials.
On the 25th, Jeon Bong-min (Independent Representative) made the announcement through the 'COVID-19 treatment/vaccine development project, abandonment of the 2nd selection project agreement in 2020' submitted by the MO
Lee, Jeong-Hwan(junghwanss@dailypharm.com)
If you want to see the full article, please JOIN US (click)